Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

GABAPENTIN 250 MG/5 ML SOLN

GABAPENTIN
$0.0862per ML
High Outlier

Strength

250 mg/5mL

Manufacturer

Camber Pharmaceuticals Inc.

NDC

31722006947

Classification

Generic

Dosage Form

SOLUTION

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

GABAPENTIN

Approval Type

Generic (ANDA)

FDA Application

ANDA217682

On Market Since

1/17/2024

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price History

1W

0.0%

1M

+1.1%

3M

+2.4%

6M

-0.6%

1Y

-3.8%

3Y

N/A

5Y

N/A

All

-31.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

GABAPENTIN 100 MG CAPSULE
Generic
00480349405•Teva Pharmaceuticals USA Inc.
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
00904666561•Major Pharmaceuticals
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
16571086701•Rising Pharma Holdings Inc.
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
16571086710•Rising Pharma Holdings Inc.
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
16571086750•Rising Pharma Holdings Inc.
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
16714066101•NorthStar Rx LLC
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
16714066102•NorthStar Rx LLC
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
23155086601•Heritage Pharmaceuticals Inc.
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
23155086605•Heritage Pharmaceuticals Inc.
$0.0211
per EA
GABAPENTIN 100 MG CAPSULE
Generic
31722014801•Camber Pharmaceuticals Inc.
$0.0211
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy